Hematopoiesis News Volume 13.27 | July 12 2022

    By
    lbeveridge
    -
    0
    30








    2022-07-12 | HN 13.26


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.26 – 12 July, 2022
    TOP STORY

    Amino Acid Catabolism Regulates Hematopoietic Stem Cell Proteostasis via a GCN2-eIF2α Axis

    Investigators demonstrated that homeostatic HSCs exhibited high amino acid (AA) catabolism to reduce cellular AA levels, which activated the GCN2-eIF2α axis, a protein synthesis inhibitory checkpoint to restrain protein synthesis for maintenance.
    [Cell Stem Cell]

    AbstractGraphical Abstract
    Explore tools and resources for your return to the lab
    PUBLICATIONSRanked by the impact factor of the journal

    Hematopoietic Transcription Factor GFI1 Promotes Anchorage Independence by Sustaining ERK Activity in Cancer Cells

    Scientists identified growth factor independent-1 (GFI1), a transcription factor that drives transition from adherent endothelial cells to suspended hematopoietic cells during hematopoiesis, as a critical regulator of anchorage-independence in lung cancer cells.
    [Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    Developmental Changes in Iron Metabolism and Erythropoiesis in Mice with Human Gain-of-Function Erythropoietin Receptor

    Prenatally and perinatally, mtHEPOR heterozygous and homozygous mice had increased Erfe transcripts, reduced hepcidin, and iron deficiency.
    [American Journal of Hematology]

    Abstract

    Microarrayed Human Bone Marrow Organoids for Modeling Blood Stem Cell Dynamics

    Researchers built a 3D in vitro model system of bone marrow (BM) organoids that recapitulated several structural and cellular components of native BM.
    [APL Bioengineering]

    Full Article

    Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched Hematopoietic Stem Cell Transplantation

    The authors investigated the potential impact of donor rs2204985 genotype on patient’s outcome after unrelated hematopoietic stem cell transplantation.
    [Bone Marrow Transplantation]

    Full Article

    Generation of the UAE’s First Emirati Induced Pluripotent Stem Cell Line KUSTi001-A from Peripheral Blood Derived CD34+ Hematopoietic Cells

    20 days post-reprogramming colonies were manually picked, and expanded clones were verified for transgene clearance by RT-PCR.
    [Stem Cell Research]

    Full Article

    Combination of Midostaurin and ATRA Exerts Dose-Dependent Dual Effects on Acute Myeloid Leukemia Cells with Wild Type FLT3

    Midostaurin combined with all-trans retinoic acid (ATRA) exerted antitumor activity against AML with wild-type FLT3 mutations in vitro and in vivo.
    [BMC Cancer]

    Full Article

    RHEB Is a Potential Therapeutic Target in T Cell Acute Lymphoblastic Leukemia

    Researchers established an single guide RNA library that comprehensively targeted mTOR upstream and downstream pathways, including autophagy.
    [Biochemical and Biophysical Research Communications]

    Abstract

    Eprenetapopt Plus Azacitidine after Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Scientists conducted a Phase II, multicenter, open-label trial to assess efficacy and safety of eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic stem-cell transplant.
    [Journal of Clinical Oncology]

    Abstract
    Request your free copy of the 'Frequencies of Cell Types in Human Peripheral Blood' Wallchart
    REVIEWS

    Metabolic Regulation of Hematopoietic Stem Cells

    The authors discuss recent insights into the regulatory roles of cellular metabolism in HSCs.
    [HemaSphere]

    Full Article

    INDUSTRY AND POLICY NEWS

    CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (Mitapivat) to Treat Children with Rare Blood Disease

    Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc. Agios’ PYRUKYND® is a first-in-class, selective, small molecule activator of the pyruvate kinase enzyme.
    [Centogene N.V.]

    Press Release

    FEATURED EVENT

    EHA Research Conference 2022

    October 17 – 20, 2022
    Palermo, Italy

    > See All Events

    JOB OPPORTUNITIES

    Associate Professor – Thematic Research Programs

    The Chinese University of Hong Kong – Hong Kong, China

    Associate Professor – Oncology

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    Scientific Editor – Blood Cancer Discovery

    American Association for Cancer Research – Various, United States

    Postdoctoral Training Fellow – Applied Biotechnology

    Francis Crick Institute – London, England, United Kingdom

    Postdoctoral Fellow – Microenvironment and Signaling

    Albert Einstein College of Medicine – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter